Tuesday, October 4, 2022


Biotechnology News Magazine

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial evaluating lead drug candidate LB1148* for accelerating return of bowel function associated with gastrointestinal (GI) surgery.

The PROFILE study in China is a randomized, double-blind, multicenter, Phase 2 trial that has enrolled over 120 patients undergoing elective bowel resection. Patients received an oral dose of LB1148 prior to surgery. The primary endpoint of clinical efficacy is the time to return of bowel function.

“Completing the PROFILE study in China is a significant milestone for Palisade Bio in our mission to bring innovative treatments to the millions of people undergoing gastrointestinal surgery across the globe. We eagerly look forward to results from this trial,” said Tom Hallam, Ph.D., CEO of Palisade Bio. “We are thankful for the unwavering commitment, support, and enthusiasm of our co-development partner Newsoara, the investigators and clinicians involved in executing this trial and are incredibly grateful to the patients who volunteered to participate in the study. We hope the data from this trial build on the early efficacy signals observed in a previous clinical study in GI surgery. Positive data would be a transformative milestone to help advance LB1148 towards eventual approval for surgical indications.”

Dr. Benny Li, CEO of Newsoara, added, “We are maintaining focus on high quality trial conduct over the course of the study. New treatment options for accelerating the return of bowel function after surgery are desperately needed. We believe LB1148 has the potential to improve the return of GI function for patients undergoing GI surgery to address this significant unmet need. By completing this study, we have achieved the next milestone on our path to potentially delivering LB1148 as the first therapy indicated for accelerating return of bowel function in China.”

Previously Palisade Bio described statistically significant data from the Phase 1, single-site, open-label, investigator-sponsored trial, called LBS-IST-POI-101, that enrolled 11 and evaluated 10 patients at a hospital in the United States. The trial evaluated the use of LB1148 for safety and preliminary efficacy in subjects undergoing elective bowel resection. LB1148 treated patients had a statistically significant reduction in hospital length of stay by 1.3-days when compared with expected length of stay based on their billing code at admission.

*LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine